TY - JOUR
T1 - Diffusion weighted magnetic resonance imaging of pre and post treatment nasopharyngeal carcinoma
AU - Hirshoren, Nir
AU - Damti, S.
AU - Weinberger, Jeffrey M.
AU - Meirovitz, Amichay
AU - Sosna, J.
AU - Eliashar, Ron
AU - Eliahou, Ruth
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Objectives: To evaluate the utility of different Apparent Diffusion Coefficient (ADC) values on Diffused Weighted Magnetic Resonance Imaging (DW-MRI) for nasopharyngeal carcinoma (NPC). Study design and setting: A retrospective cohort study in a single tertiary medical center. Subjects and methods: The study group consists of patients with pathology proven NPC that underwent DW-MRI prior or/and following a non-surgical chemo radiation treatment between the years 2007 and 2017. ADC thresholds were analyzed and compared for primary (pre-treatment) and expected post-irradiation NPC cases and healthy controls. Results: We recruited 144 patients who underwent 195 MRI's for NPC. 25 DW-MRI were performed before (primary, active NPC) and 56 following (no residual NPC) treatment. 45 out of 225 patients who had brain DW-MRI for other reasons (control group) had measurable nasopharynx tissue (N = 33, adjusted for age and gender). The mean ADC of NPC prior to treatment (0.69 ± 0.13 × 10−3 mm2/s) was significantly lower (ANOVA, P < 0.001) compared to the mean ADC of the adjusted controls (1.11 ± 0.25 × 10−3 mm2/s) and post-treatment (1.49 ± 0.28 × 10−3 mm2/s) groups. An ADC threshold of 0.805 × 10−3 mm2/s had 94% and 93.9% sensitivity and specificity rates, respectively and an odds ratio of 175[95%CI(23.25–1000)], comparing ADC levels of pre-treatment NPC patients and adjusted control group. An ADC threshold of 0.965 × 10−3 mm2/s yielded 100% positive and negative predicted values distinguishing pre-treatment and post-treatment NPC patients (free of disease). There was no statistical association between ADC levels and tumor volume/stage, nodal stage or group staging. Conclusions: ADC levels have distinct values in newly diagnosed and follow up of NPC.
AB - Objectives: To evaluate the utility of different Apparent Diffusion Coefficient (ADC) values on Diffused Weighted Magnetic Resonance Imaging (DW-MRI) for nasopharyngeal carcinoma (NPC). Study design and setting: A retrospective cohort study in a single tertiary medical center. Subjects and methods: The study group consists of patients with pathology proven NPC that underwent DW-MRI prior or/and following a non-surgical chemo radiation treatment between the years 2007 and 2017. ADC thresholds were analyzed and compared for primary (pre-treatment) and expected post-irradiation NPC cases and healthy controls. Results: We recruited 144 patients who underwent 195 MRI's for NPC. 25 DW-MRI were performed before (primary, active NPC) and 56 following (no residual NPC) treatment. 45 out of 225 patients who had brain DW-MRI for other reasons (control group) had measurable nasopharynx tissue (N = 33, adjusted for age and gender). The mean ADC of NPC prior to treatment (0.69 ± 0.13 × 10−3 mm2/s) was significantly lower (ANOVA, P < 0.001) compared to the mean ADC of the adjusted controls (1.11 ± 0.25 × 10−3 mm2/s) and post-treatment (1.49 ± 0.28 × 10−3 mm2/s) groups. An ADC threshold of 0.805 × 10−3 mm2/s had 94% and 93.9% sensitivity and specificity rates, respectively and an odds ratio of 175[95%CI(23.25–1000)], comparing ADC levels of pre-treatment NPC patients and adjusted control group. An ADC threshold of 0.965 × 10−3 mm2/s yielded 100% positive and negative predicted values distinguishing pre-treatment and post-treatment NPC patients (free of disease). There was no statistical association between ADC levels and tumor volume/stage, nodal stage or group staging. Conclusions: ADC levels have distinct values in newly diagnosed and follow up of NPC.
KW - Apparent diffusion coefficient
KW - Cancer detection
KW - Diffused weighted magnetic resonance imaging
KW - Nasopharyngeal carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85069668326&partnerID=8YFLogxK
U2 - 10.1016/j.suronc.2019.07.005
DO - 10.1016/j.suronc.2019.07.005
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31500774
AN - SCOPUS:85069668326
SN - 0960-7404
VL - 30
SP - 122
EP - 125
JO - Surgical Oncology
JF - Surgical Oncology
ER -